Investors fund programs with a clear path to launch.

Understand why manufacturing and safety strategy matter early—and how CMC and tox shape investor confidence and program value.

This episode demystifies CMC and toxicology—and explains why they matter far earlier than most founders expect. Dr. Silvon shows how manufacturing and safety planning shape investor confidence, regulatory credibility, and program value. You’ll learn what questions investors are asking even when they don’t say so, and how early technical rigor can de-risk your program. If you’ve ever felt unprepared discussing development strategy, scalability, or safety planning, this conversation gives you the understanding and language needed to engage confidently and position your company for funding and long-term success.